Edition:
United States

Citius Reports Progress In Hemorroid Treatment Program


Tuesday, 6 Mar 2018 08:00am EST 

March 6 (Reuters) - Citius Pharmaceuticals Inc ::CITIUS REPORTS PROGRESS IN HEMORROID TREATMENT PROGRAM.CITIUS PHARMACEUTICALS - SELECTING HIGHER POTENCY CORTICOSTEROID IN ITS STEROID/ANESTHETIC TOPICAL FORMULATION PROGRAM FOR TREATMENT OF HEMORRHOIDS.CITIUS PHARMACEUTICALS INC - NEW FORMULATION, CITI-002, WILL COMBINE LIDOCAINE WITH HIGHER POTENCY CORTICOSTEROID.CITIUS PHARMACEUTICALS INC - HELD A TYPE C MEETING WITH FDA TO DISCUSS RESULTS OF PHASE 2A STUDY.CITIUS PHARMACEUTICALS - MEETING WITH FDA ALSO TO OBTAIN ITS VIEW ON PLANS TO SUPPORT POTENTIAL FORMULATION CHANGE FOR PLANNED PHASE 2B STUDY.CITIUS PHARMACEUTICALS INC - REQUESTED FDA'S FEEDBACK ON PHASE 2B STUDY DESIGN.CITIUS PHARMACEUTICALS - PRE-CLINICAL, CLINICAL DEVELOPMENT PROGRAMS FOR CITI-002 PLANNED TO BE SIMILAR TO THOSE OF CITI-001. 

Company Quote

1.09
 --
20 Feb 2019